Rezolute Announces Preliminary Phase 3 Clinical Trial Results and $100 Million Public Offering
RZLT Rezolute Inc
$3.65 -5.56%
View chart & analysis → - 1Rezolute Inc shares rose 7.8% during Wednesday pre-market trading.
- 2Rezolute Inc announced that it met the primary efficacy endpoint in preliminary Phase 3 clinical trial results for its hyperinsulinism treatment.
- 3Rezolute Inc offered 22,040,976 shares of common stock at $3.87 per share to target a $100 million public offering.
So what's the key point?
Rezolute Inc obtained positive results from its final trial to confirm the effectiveness of its drug. Shares rose 7.8% on the news, and the company is raising $100 million in funds.
Source Nasdaq +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.